ES-SCLC is a form of lung cancer accounting for one in eight lung cancer cases in the UK. It is an aggressive disease that progresses rapidly, with a significant negative impact on the quality of ...

PD-1 and PD-L1 inhibitors combined with chemotherapy significantly improve survival in ES-SCLC compared with chemotherapy alone. No significant difference in overall survival or progression-free ...

Imfinzi is already approved for the treatment of extensive-stage SCLC (ES-SCLC) in the United States, European Union, Japan, China and several other countries across the world. The approval in the ...

The indicated population includes adult patients with extensive-stage small cell lung cancer (ES-SCLC) whose disease has progressed on or after platinum-based chemotherapy. Gilead’s Trodelvy is ...

Dosing has started in a clinical evaluating peluntamig, which targets DLL3 and CD47, combined with chemotherapy in patients with DLL3-expressing cancers.

Henlius' commitment to stringent quality standards has been instrumental in achieving EC approval for serplulimab. In 2023, Henlius' manufacturing facilities and production lines of serplulimab ...

This approval establishes serplulimab as the first and only anti-PD-1 mAb approved in the EU for the treatment of ES-SCLC. Serplulimab is the world's first anti-PD-1 mAb approved for first-line ...

This approval establishes serplulimab as the first and only anti-PD-1 mAb approved in the EU for the treatment of ES-SCLC. Dr. Jason Zhu, Executive Director and Chief Executive Officer of Henlius, ...